2010 OPEN FORUM Abstracts
EVALUATING SAFETY AND CLINICAL FEASIBILITY OF AN IN-LINE MICROPUMP NEBULIZER FOR AEROSOL DRUG DELIVERY DURING HIGH FREQUENCY OSCILLATORY VENTILATION.
Scott T. Dwyer, Stairhime Robert, Annette Dekker, John Hunt, Michael D. Davis; University of Virginia, Charlottesville, VA
Introduction/Purpose: The delivery of aerosolized medications during high frequency oscillatory ventilation (HFOV) presents several known problems. This study explored the safety and efficacy of using a micropump nebulizer (Aeroneb Pro-X, Aerogen Ltd, Galway, Ireland) in conjunction with HFOV. Methods: A broad spectrum of ventilatory settings was applied to a Viasys/Sensormedics 3100A oscillator (Yorba Linda, CA) attached to a test lung. The settings used included the clinically applicable ranges of frequency, inspiratory time (%IT), and power. Mean airway pressure (Paw) and amplitude were recorded before and after introduction of an in-line micropump nebulizer at each setting. Results: Oscillator function was not significantly altered by introduction of in-line micropump nebulization. Mean airway pressures taken during aerosol delivery were an average of 4.08% (25-75 range of -0.01, 0.1) lower than Paw taken immediately prior using identical ventilator settings. Also, amplitude did not vary with addition of the nebulizer. Conclusions: Micropump nebulizers are a safe method for aerosol drug delivery to patients undergoing HFOV. The implications of these data will aid the respiratory care clinician in providing optimal care for patients requiring aerosol medications and mechanical ventilation. Sponsored Research - Nebulizer provided by Aerogen Ltd.